Beating many analysts’ expectations for the final quarter of 2020, Bristol Myers Squibb (NYSE: BMY) reported sales of $11.1 billion in its annual results statement, yielding full-year revenues of $42.5 billion.
The 39% increase was driven primarily by the impact of the firm’s acquisition of Celgene, which was completed in November 2019.
The results reflect exceptional expenses, including the cost of buying Celgene, leading to a loss per share of $4.45 following Generally Accepted Accounting Principles (GAAP).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze